Eltrombopag 25mg (Eltrombopag)
Description of Revolade 25mg (Eltrombopag 25mg)
Revolade 25mg (Eltrombopag 25mg) is a prescription medicine which is used under the guidance of the doctor.
Revolade 25mg (Eltrombopag 25mg) medicine may be used as part of a combination therapy. Thereby medicine may need to take it with other medications.
Medical use /Indication of Revolade 25mg (Eltrombopag 25mg)
Revolade 25mg (Eltrombopag 25mg) is mainly indicated for the treatment of patients having :
- Reduced platelet levels due to chronic immune thrombocytopenia
- Reduced platelet counts due to chronic hepatitis C virus infection
Severe aplastic Anemia :
- First line treatment of severe aplastic Anemia
- Treatment of refractory severe aplastic Anemia
Mechanism of Action Revolade 25mg (Eltrombopag 25mg)
Revolade be part of class of medicines called thrombopoietin (TPO) receptor agonists. A classification of medicines is aassociation of medications which work in a similar way. These medicines are often used to treat similar conditions. Revolade works by raise cells in bone marrow andleads these cells to make various platelets. This effect reducesthe risk of bleeding.
Absorption of Revolade 25mg (Eltrombopag 25mg)
peak plasma concentration is 2-6 hours
Distribution of Revolade 25mg (Eltrombopag 25mg)
highly human plasma protein bounding is >99% and in blood plasma level is 50% to 79%
Metabolism of Revolade 25mg (Eltrombopag 25mg)
predominantly metabolised through cleavage, oxidation and conjugation with glucuronic acid.
Excretion of Revolade 25mg (Eltrombopag 25mg)
Revolade 25mg (Eltrombopag 25mg) eliminated primarily via feces 59%, along with 31% via renally excreted
Half-life of Revolade 25mg (Eltrombopag 25mg) healthy patients is 21-23 hours and idiopathic thrombocytopenic purpura is 26-35 hours.
Side effects of Revolade 25mg (Eltrombopag 25mg)
Common side effects:
- low red blood cells
- pain in head
- decreased appetite
Serious side effects:
- Urine in dark colour
- Yellowing of your skin
- Abdomen swelling
- Chest pain
- Cloudy vision
- Sensitivity to light
- Seeing circles around lights
- Swelling of legs.
Precautions of Revolade 25mg (Eltrombopag 25mg)
The medicine causes warning condition, call the doctor while new medication interaction Disease progression warning: Avoid using the medicine ug while the patients have myelodysplastic syndrome (MDS), will increases the risk of death.
If other blood clot risk factors, then avoid the medicine because it will increase platelet counts and blood clots.
If the patients have cataracts, avoid the medicine due to the medicine effects cataracts and make the condition worse.
Drug interaction of Revolade 25mg (Eltrombopag 25mg)
- Revolade 25mg (Eltrombopag 25mg)interaction with these medicines ezetimibe, glyburide, Olmesartan, repaglinide, valsartan, imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, Bosentan, sulfasalazine, and topotecan irinotecan leads increase of side effects. hence the doctor may reduce your dosage of these medicines if required.
- Revolade 25mg (Eltrombopag 25mg) co administration with Cholesterol-reducing medicines like atorvastatin, fluvastatin, rosuvastatin, pravastatin, and simvastatin, pitavastatin. Have high side effects can contains muscle pain. The doctor may reduce the dosage of your cholesterol medicines .
- Revolade 25mg (Eltrombopag 25mg) concomitant use with Antacids, vitamins, or supplements which involves Ca, Al, Fe, Se, Zn, or Mg. To stop interactions, then take Revolade two hours before or four hours after administrating any of these products.
Pregnancy of Revolade 25mg (Eltrombopag 25mg)
Pregnancy category is C
Use the Revolade 25mg (Eltrombopag 25mg) with caution if asset outweigh risks. Animal studies reveal risk and human studies not available or neither animal nor human studies done.
Lactation of Revolade 25mg (Eltrombopag 25mg)
The presence of Revolade 25mg (Eltrombopag 25mg) or metabolites in human milk, the medicine has possible serious side effects for breastfed child. The medicine is not recommended during breast feeding
Dosage of Revolade 25mg (Eltrombopag 25mg)
Chronic Immune Thrombocytopenia :
Indicated only in patients with chronic immune thrombocytopenia whose clinical condition increases bleeding risk
Initial: 50 mg PO qDay
Adjust dose to achieve and control platelet count (Plt) >50 x 10^9/L to lowers risk of bleeding; not to exceed 75 mg/day Chronic Hepatitis C-associated Thrombocytopenia
Initial: 25 mg PO qDay
Dose is Adjust in 25 mg accretion q2weeks PRN to attain target Pltneeded to start/control antiviral therapy with pegylated interferon and ribavirin; not to exceed 100 mg/day
During antiviral therapy, regulate dose to stop dose reductions of peginterferon
Severe Aplastic Anemia
First-line therapy :
Concomitant use with standard immunosuppressive therapy, for patients with serious aplastic Anemia (SAA)
Usual dose: 150 mg PO qDay for 6 months
Do not give more thanstarting dose; total duration is 6 months
Refractory SAA :
The medicine given for this condition who fail to respond sufficient to at least 1 before immunosuppressive therapy
50 mg PO qDay
Adjust dose in 50-mg accretion q2Weeks PRN to attain target Plt ≥50 x 10^9/L as required; not exceed 150 mg/day; may take up to 16 weeks for hematologic response.
Storage of Revolade 25mg (Eltrombopag 25mg)
Store at room temperature 20℃ and 25℃.
Discard the left-out medicine if not used within 30 minutes
Missed dose of Revolade 25mg (Eltrombopag 25mg)
In case of missed dose, patients must consult with medical practitioner and follow the instructions given by them. thereby missed dose should be avoid and follow the regular dosing schedule.
No reviews found